869 results on '"Elias, Sjoerd G."'
Search Results
2. Holmium-166 radioembolisation dosimetry in HCC
3. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response
4. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)
5. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease
6. Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer
7. Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference—a Dutch population-based study from 2008 to 2018
8. EGFR-targeted fluorescence molecular imaging for intraoperative margin assessment in oral cancer patients: a phase II trial
9. Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification
10. CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma
11. Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial
12. Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness: During or After Chemotherapy
13. Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study
14. Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity
15. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
16. Effects of exercise in breast cancer patients: implications of the trials within cohorts (TwiCs) design in the UMBRELLA Fit trial
17. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)
18. Oncologic outcomes of screen-detected and non-screen-detected T1 colorectal cancers
19. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response
20. Oncologic outcomes of screen-detected and non-screen-detected T1 colorectal cancers
21. A prediction model for response to immune checkpoint inhibition in advanced melanoma
22. A prediction model for response to immune checkpoint inhibition in advanced melanoma
23. Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer
24. The prognostic potential of mammographic growth rate of invasive breast cancer in the Nijmegen breast cancer screening cohort.
25. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease.
26. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study
27. Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations
28. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease
29. Oncological outcomes of screen-detected and non-screen-detected T1 colorectal cancers
30. A prediction model for response to immune checkpoint inhibition in advanced melanoma
31. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study
32. Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index
33. Quantifying the Mitigating Effects of Whole-Breast Radiotherapy and Systemic Treatments on Regional Recurrence Incidence Among Breast Cancer Patients
34. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
35. Development and validation of a lifestyle-based model for colorectal cancer risk prediction: the LiFeCRC score
36. Pedunculated Morphology of T1 Colorectal Tumors Associates With Reduced Risk of Adverse Outcome
37. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response
38. Increased Levels of Oxidative Damage in Liver Metastases Compared with Corresponding Primary Colorectal Tumors: Association with Molecular Subtype and Prior Treatment
39. Histologic Factors Associated With Need for Surgery in Patients With Pedunculated T1 Colorectal Carcinomas
40. Triple-Negative and Non–Triple-Negative Invasive Breast Cancer: Association between MR and Fluorine 18 Fluorodeoxyglucose PET Imaging
41. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
42. Integrating molecular nuclear imaging in clinical research to improve anticancer therapy
43. Discovery of common and rare genetic risk variants for colorectal cancer
44. Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer
45. Published diagnostic models safely excluded colorectal cancer in an independent primary care validation study
46. Mode of progression after radioembolization in patients with colorectal cancer liver metastases
47. Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer
48. Correlation between Histopathological Prognostic Tumor Characteristics and [ 18 F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.
49. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
50. Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.